

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of  
CHANG et al.

Customer No.: 51957

Serial No: 10/685,941

Filed: October 14, 2003

For: COMBINATION OF BRIMONIDINE  
AND TIMOLOL FOR TOPICAL  
OPHTHALMIC USE

Group Art Unit: 1614

Examiner: Brian S. Kwon

Confirmation No. 7685  
FILED ELECTRONICALLY

Commissioner for Patents  
Alexandria, VA 22313-1450

Dear Sir:

Transmitted herewith is a Reply to the Office Action dated February 13, 2007 on the above-identified application.

[ X] Reply (4 pages)

[ X] The fee has been calculated as shown below.

[ X] Terminal Disclaimer and fee of \$30.00 (2 pages)

[ X] Declaration of an Expert (4 pages)

CLAIMS	COLUMN A <i>Claims Remaining After Amendment</i>	COLUMN B <i>Highest Number Previously Paid</i>	COLUMN C <i>Present Extra</i>	<i>Rate</i>	<i>Additional Fee</i>
<i>Total</i>	1	20	0	x \$50	\$ .00
<i>Independent</i>	1	3	0	x \$200	\$ .00
[ ] First Presentation of Multiple Dep. Claim x \$280 = \$ .00					
Time Extension Fees:					\$ .00
Terminal Disclaimer Fee					\$130
Total Due:					\$130.00

The Commissioner is hereby authorized to charge payment of any additional fees required under 37 CFR 1.16, or credit any overpayment, to Deposit Account No. 01-0885.

Date: March 8, 2007

/Brent A. Johnson/  
Brent A. Johnson  
Registration No. 51,851  
ALLERGAN, INC. (T2-7H)  
2525 Dupont Drive  
Irvine, CA 92612  
Telephone No. (714) 246-4348  
Telecopier: (714) 246-4249